|
|
|
| A case report and literature review treatment of squamous cell lung cancer combined with pulmonary sarcomatoid carcinoma |
| LONG Yunzhi1 ZHANG Xiangyan2▲ SHAO Songjun2 WANG Guoyu2 |
1.Graduate School of Guizhou Medical University, Guizhou Province, Guiyang 550004, China;
2.Department of Respiratory and Critical Medicine, Affiliated People’s Hospital of Guizhou Medical University Guizhou Provincial People’s Hospital, Guizhou Province, Guiyang 550002, China |
|
|
|
Abstract Squamous cell lung cancer is a unique histological subtype of non-small cell lung cancer, its special clinicopathological features and molecular background determine the limitation of its treatment, pulmonary sarcomatoid canceration is a type of non-small cell lung cancer, contains elements of sarcoma or sarcomatoid differentiation. A malignant tumor of mixed epithelial and mesenchymal tissue, represents a whole continuum of epithelial and mesenchymal differentiation. It is a kind of poorly differentiated lung malignant tumor with rapid clinical progress and rare occurrence. It is rare to have both, treatment is also tricky. Combined with relevant literature review, the clinical data of a patient diagnosed with squamous cell lung cancer complicated with pulmonary sarcomatoid canceration recently admitted to the Department of Respiratory and Critical Medicine of the Affiliated People’s Hospital of Guizhou Medical University were analyzed, in order to improve clinicians’ understanding of the disease.
|
|
|
|
|
|
[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Duma N，Santana-Davila R，Molina JR. Non-Small Cell Lung Cancer：Epidemiology，Screening，Diagnosis，and Treatment [J]. Mayo Clin Proc，2019，94（8）：1623-1640.
[3] Yendamuri S，Caty L，Pine M，et al. Outcomes of sarcomatoid carcinoma of the lung：a Surveillance，Epidemiology，and End Results Database analysis [J]. Surgery，2012，152（3）：397-402.
[4] Sun L，Dai J，Chen Y，et al. Pulmonary Sarcomatoid Carcinoma：Experience From SEER Database and Shanghai Pulmonary Hospital [J]. Ann Thorac Surg，2020，110（2）：406-413.
[5] Socinski MA，Obasaju C，Gandara D，et al. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer [J]. J Thorac Oncol，2018，13（2）：165-183.
[6] Socinski MA，Obasaju C，Gandara D，et al. Clinicopathologic Features of Advanced Squamous NSCLC [J]. J Thorac Oncol，2016，11（9）：1411-1422.
[7] Travis WD，Brambilla E，Nicholson AG，et al. The 2015 World Health Organization Classification of Lung Tumors：Impact of Genetic，Clinical and Radiologic Advances Since the 2004 Classification [J]. J Thorac Oncol，2015，10（9）：1243-1260.
[8] 张杰，邵晋晨，朱蕾.2015版WHO肺肿瘤分类解读[J].中华病理学杂志，2015，44（9）：619-624.
[9] Steuer CE，Behera M，Liu Y，et al. Pulmonary Sarcomatoid Carcinoma：An Analysis of the National Cancer Data Base [J]. Clin Lung Cancer，2017，18（3）：286-292.
[10] Manzotti G，Torricelli F，Benedetta D，et al. An Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma （PSC） and Identifies Dasatinib as New Therapeutic Option [J]. Clin Cancer Res，2019，25（7）：2348-2360.
[11] Weissferdt A，Kalhor N，Rodriguez CJ，et al. Spindle cell and pleomorphic （“sarcomatoid”） carcinomas of the lung：an immunohistochemical analysis of 86 cases [J]. Hum Pathol，2017，59（4）：1-9.
[12] 王丽丽，张静，梁小龙，等.肺肉瘤样癌的临床病理特征及分子特点研究进展[J].中华肺部疾病杂志（电子版），2017，10（1）：83-86.
[13] 顾海艇，周建娅，吴挺，等.肺肉瘤样癌患者的临床特征及预后分析[J].中华医学杂志，2018，98（10）：744-748.
[14] Smadhi H，Boudaya MS，Abdannadher M，et al. Pulmonary Sarcomatoid carcinoma：a surgical diagnosis and prognostic factors [J]. Tunis Med，2019，97（1）：128-132.
[15] Rahouma M，Kamel M，Narula N，et al. Pulmonary sarcomatoid carcinoma：an analysis of a rare cancer from the Surveillance，Epidemiology，and End Results database [J]. Eur J Cardiothorac Surg，2018，53（4）：828-834.
[16] Fallet V，Saffroy R，Girard N，et al. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta Panel：exploring therapeutic targets [J]. Ann Oncol，2015，26（8）：1748-1753.
[17] Schrock AB，Li SD，Frampton GM，et al. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling [J]. J Thorac Oncol，2017，12（6）：932-942.
[18] Kim S，Kim MY，Koh J，et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung：Comparison of sarcomatous and carcinomatous areas [J]. Eur J Cancer，2015，51（17）：2698-2707.
[19] Kim HR，Cha YJ，Hong MH，et al. Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization [J]. Oncotarget，2017，8（50）：87234-87243.
[20] 赵沙，蒋涛，周彩存.抗PD-1/PD-L1免疫治疗疗效预测标志物在非小细胞肺癌中的研究进展[J].肿瘤，2016，36（7）：823-828.
[21] Ruiz-Cordero R，Devine WP. Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer [J]. Surg Pathol Clin，2020，13（1）：17-33.
[22] Paz-Ares L，Vicente D，Tafreshi A，et al. A Randomized，Placebo-Controlled Trial of Pembrolizumab Plus Chem-otherapy in Patients With Metastatic Squamous NSCLC：Protocol-Specified Final Analysis of KEYNOTE-407 [J]. J Thorac Oncol，2020，15（10）：1657-1669.
[23] Jotte R，Cappuzzo F，Vynnychenko I，et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC （IMpower131）：Results From a Randomized Phase Ⅲ Trial [J]. J Thorac Oncol，2020，15（8）：1351-1360.
[24] Zhang Y，Zhou H，Zhang L. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy：anti-PD-1 or anti-PD-L1? [J]. J Immunother Cancer，2018，6（1）：135-144.
[25] 中华医学会，中华医学会肿瘤分会，中华医学会杂志社.中华医学会肺癌临床诊疗指南（2018版）[J].中华肿瘤杂志，2018，40（12）：935-964. |
|
|
|
